- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00446264
Islet Allotransplantation With Steroid Free Immunosuppression
Sequential Islet Transplantation With Steroid Free Immunosuppression for Type 1 Diabetes
The restoration of endogenous insulin secretion carries significant hopes for shifting the paradigm of life long exogenous insulin therapy in selected groups of patients with type 1 diabetes(T1D). After decades of frustrating clinical attempts, the Edmonton group set up in 2000 new standards for islet transplantation in patients with brittle T1D by achieving insulin independence in 80 percent of patients. These seminal results have however proved much more difficult to duplicate than initially expected.
This single center phase 2 clinical trial, duplicating the Edmonton protocol, is designed for confirming the consistent short term efficacy and safety of sequential islet allotransplantation with steroid free immunosuppression in patients with severe T1D.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The short term effectiveness of islet transplantation for alleviating hypoglycemia and controlling glucose homeostasis while limiting or even avoiding the nedd for exogenous insulin has been established despite protocol modifications in donor selection, islet preparation or recipient treatment, insulin independence with adequate metabolic control was however rarely prolonged beyond two years. The most frequently proposed explanations include chronic allogenic rejection, recurrence of autoimmunity and beta cell toxicity from administered immunosuppressive drugs.
Fourteen patients were enrolled in this single center phase 2 trial initiated in 2003. Eligible patients were males or females between 18 and 65 years of age, with type 1 diabeted documented for more than 5 years, arginine stimulated C-peptide lower than 0.2ng/ml, and hypoglycemia awareness or documented metabolic lability. Exclusion criteria included body mass index greater than 28Kg/m2, unstable arteriopathy or heart disease, active infection, previous transplantation, insulin daily requirements above 1.2 UI/kg, creatinin clearance below 60 ml/mn/m2 or urinary albumin excretion above 300 mg/day, malignancy, smoking, desire for pregnancy, psychiatric disorders and lack of compliance. The study primary efficacy endpoint was graft survival defined as insulin independence and HbA1c<6.5%. Secondary outcomes were graft function and metabolic control.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
-
Lille, Frankrijk, 59037
- University Hospital of Lille
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- type 1 diabetes documented for more than 5 years
- arginine stimulated C-peptide lower than 0.2 ng/mL
- one of the following:hypoglycemia unawareness OR metabolic lability documented by one or more severe hypoglycemias or two or more hospital admissions for ketoacidosis within the previous year.
Exclusion Criteria:
- body mass index greater than 28 kg/m2
- non stable arteriopathy or heart disease
- active infection
- previous transplantation
- hyperimmunization
- insulin daily needs above 1.2 U/Kg
- creatinine clearance below 60 ml/mn or urinary albumin excretion above 300 mg/d
- malignancy
- smoking
- desire for pregnancy
- psychiatric disorders
- lack of compliance
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: islet transplantation
Each participant received up to three sequential fresh islet infusions within three months.
|
Eilandjestransplantatie bestond uit maximaal drie opeenvolgende infusies van verse eilandjes binnen drie maanden.
Toegang tot de poortader werd verkregen onder algemene anesthesie door percutane katheterisatie van een perifere poortader onder echogeleide of door chirurgische katheterisatie van een kleine mesenteriale ader.
Andere namen:
Immunosuppressive consisted of Tacrolimus, target through level at 3-6 ng/ml, Sirolimus, target through level at 12-15 ng/ml for three months and at 7-10 ng/ml thereafter.
A five-dose induction course of Daclizumab 1mg/Kg was administered biweekly beginning one hour prior to the first infusion
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Composite Criteria: Insulin Independence and Glycosylated Hemoglobin (HbA1c) Under 6.5% at One Year
Tijdsspanne: 1 year
|
The percentage of insulin independents subjects with an HbA1c less than 6.5% at one year after last transplant
|
1 year
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Hypoglycemic Events
Tijdsspanne: day 0 to day 365
|
Percentage of subjects free of severe hypoglycemic events from day 0 to day 365 with the day of transplant designated day 0
|
day 0 to day 365
|
|
Plasma C-peptide
Tijdsspanne: 1 year
|
Level of plasma C-peptide at 1 year after the first transplant
|
1 year
|
|
HbA1c < 6.5%
Tijdsspanne: 1 year
|
The percentage of subjects with HbA1c < 6.5% at 1 year after the first transplant
|
1 year
|
|
Percentage of Time Spent in Hypoglycemia (<0.70 mg/L)
Tijdsspanne: 1 year
|
percentage of time spent in hypoglycemia derived from CGMS (Continuous Glucose Monitoring System)
|
1 year
|
|
Number of Adverse Events
Tijdsspanne: 1 year
|
The number of adverse events related to the procedure and to the immunosuppression
|
1 year
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Francois Pattou, MD, University Hospital, Lille
- Hoofdonderzoeker: Marie-Christine Vantyghem, MD PhD, University Hospital, Lille
- Hoofdonderzoeker: Julie Kerr-Conte, PhD, Université de Lille 2
Publicaties en nuttige links
Algemene publicaties
- Vantyghem MC, Chetboun M, Gmyr V, Jannin A, Espiard S, Le Mapihan K, Raverdy V, Delalleau N, Machuron F, Hubert T, Frimat M, Van Belle E, Hazzan M, Pigny P, Noel C, Caiazzo R, Kerr-Conte J, Pattou F; Members of the Spanish Back Pain Research Network Task Force for the Improvement of Inter-Disciplinary Management of Spinal Metastasis. Ten-Year Outcome of Islet Alone or Islet After Kidney Transplantation in Type 1 Diabetes: A Prospective Parallel-Arm Cohort Study. Diabetes Care. 2019 Nov;42(11):2042-2049. doi: 10.2337/dc19-0401. Erratum In: Diabetes Care. 2020 May;43(5):1164.
- Benomar K, Chetboun M, Espiard S, Jannin A, Le Mapihan K, Gmyr V, Caiazzo R, Torres F, Raverdy V, Bonner C, D'Herbomez M, Pigny P, Noel C, Kerr-Conte J, Pattou F, Vantyghem MC. Purity of islet preparations and 5-year metabolic outcome of allogenic islet transplantation. Am J Transplant. 2018 Apr;18(4):945-951. doi: 10.1111/ajt.14514. Epub 2017 Nov 11.
- Caiazzo R, Vantyghem MC, Raverdi V, Bonner C, Gmyr V, Defrance F, Leroy C, Sergent G, Hubert T, Ernst O, Noel C, Kerr-Conte J, Pattou F. Impact of Procedure-Related Complications on Long-term Islet Transplantation Outcome. Transplantation. 2015 May;99(5):979-84. doi: 10.1097/TP.0000000000000458.
- Vantyghem MC, Raverdy V, Balavoine AS, Defrance F, Caiazzo R, Arnalsteen L, Gmyr V, Hazzan M, Noel C, Kerr-Conte J, Pattou F. Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (beta-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (beta-score greater than 3). J Clin Endocrinol Metab. 2012 Nov;97(11):E2078-83. doi: 10.1210/jc.2012-2115. Epub 2012 Sep 20.
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Glucosemetabolismestoornissen
- Ziekten van het immuunsysteem
- Auto-immuunziekten
- Endocriene systeemziekten
- Suikerziekte
- Diabetes mellitus, type 1
- Hypoglykemie
- Metabole ziekten
- Fysiologische effecten van medicijnen
- Moleculaire mechanismen van farmacologische werking
- Anti-infectieuze middelen
- Enzymremmers
- Antineoplastische middelen
- Immunosuppressieve middelen
- Immunologische factoren
- Antibacteriële middelen
- Antibiotica, antineoplastiek
- Antischimmelmiddelen
- Calcineurineremmers
- Tacrolimus
- Sirolimus
- Daclizumab
Andere studie-ID-nummers
- CP 01/48
- PHRC (French Ministry of Health)
- AFSSAPS 030209 (Andere identificatie: AFSSAPS)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .